ALLO
- Allogene Therapeutics, Inc.
()
Overview
Company Summary
Allogene Therapeutics, Inc. is a biotechnology company focused on the development of innovative allogeneic CAR-T (Chimeric Antigen Receptor T-cell) therapies for cancer treatment. CAR-T therapy is an advanced form of immunotherapy that harnesses the patient's own immune system to target and destroy cancer cells.
What sets Allogene apart is its emphasis on allogeneic CAR-T therapy. Unlike autologous CAR-T therapy, where T-cells are extracted from each individual patient and modified before being infused back into the same patient, allogeneic CAR-T therapy uses healthy donor T-cells that are modified to attack cancer cells and can be given to multiple patients.
The company is dedicated to developing a broad pipeline of allogeneic CAR-T therapies for various types of cancer, including both hematologic malignancies (blood cancers) and solid tumors. Their goal is to provide more accessible and cost-effective treatments while avoiding the time-consuming and costly individualized manufacturing processes associated with autologous CAR-T therapy.
To develop their therapies, Allogene utilizes its proprietary technologies, such as gene editing techniques, to engineer the allogeneic CAR-T cells to be effective against specific targets on cancer cells. They also conduct rigorous preclinical studies and clinical trials to ensure the safety and efficacy of their therapies.
In addition to their research and development efforts, Allogene collaborates with various academic institutions and industry partners to accelerate the discovery and development of advanced CAR-T therapies. They believe in the potential of allogeneic CAR-T therapy to revolutionize cancer treatment and improve outcomes for patients.
Overall, Allogene Therapeutics, Inc. is actively working towards advancing allogeneic CAR-T therapies as a promising approach for the treatment of cancer, with the goal of making these potentially life-saving treatments more widely accessible to patients in need.